SynthesisBMC cardiovascular disorders2026
C-reactive protein-to-albumin ratio and the mortality of patients with heart failure: a meta-analysis.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe C-reactive protein-to-albumin ratio (CAR) reflects the interplay between systemic inflammation and nutritional status, and has recently been proposed as a prognostic biomarker in heart failure (HF). However, its association with mortality risk across acute decompensated HF (ADHF) and chronic HF (CHF) populations remains uncertain. This meta-analysis evaluated the relationship between baseline CAR and all-cause mortality in HF.
methodsPubMed, Embase, Web of Science, CNKI, and Wanfang were searched for relevant longitudinal studies. Risk ratios (RRs) were pooled using a random-effects model accounting for heterogeneity. Prespecified subgroup and meta-regression analyses were performed to evaluate the influence of study characteristics.
resultsTwelve cohort studies involving 6,377 patients were included. High CAR was associated with a significantly increased risk of mortality (RR = 2.34, 95% CI 1.86-2.93), with moderate heterogeneity (I² = 66%). Notably, the association was weaker in prospective studies (RR = 1.45) compared with retrospective studies (RR = 2.50). Subgroup findings were consistent across regions (Asian: RR = 2.62; Western: RR = 1.87), HF phenotype (ADHF: RR = 2.15; CHF: RR = 2.47), age (< 65 years: RR = 2.36; ≥65 years: RR = 2.33), CAR cutoff (< 0.5 mg/g: RR = 2.60; ≥0.5 mg/g: RR = 2.16), follow-up duration (< 30 months: RR = 2.20; ≥30 months: RR = 2.45), and analytic model (univariate: RR = 2.71; multivariate: RR = 1.99). Meta-regression identified no significant moderators.
conclusionsElevated baseline CAR is consistently associated with higher mortality risk in patients with HF. However, the strength of this association appears lower in prospective studies, suggesting that the overall pooled estimate may be influenced by biases inherent to retrospective designs. In addition, the clinical utility of CAR for risk stratification of patients with HF requires further validation in well-designed prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.